NCT06547099 Study to Understand Novel Biomarkers in Researching Dementia
| NCT ID | NCT06547099 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,800 participants |
| Start Date | 2024-08-14 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,800 participants in total. It began in 2024-08-14 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Eligibility Criteria
Inclusion Criteria: * At least 60 years of age * 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and/or provider * All SEABIRD participants will be invited to participate regardless of their cognitive status Exclusion Criteria: * Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment * Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection * Taking a disease-modifying drug for AD at time of enrollment * Blood transfusion in the last three months * Unwilling or unable to participate in all study activities
Contact & Investigator
Randall Bateman, MD
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT06547099 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06547099 currently recruiting?
Yes, NCT06547099 is actively recruiting participants. Contact the research team at sunbirdstudy@wustl.edu for enrollment information.
Where is the NCT06547099 trial being conducted?
This trial is being conducted at St Louis, United States.
Who is sponsoring the NCT06547099 clinical trial?
NCT06547099 is sponsored by Washington University School of Medicine. The principal investigator is Randall Bateman, MD at Washington University School of Medicine. The trial plans to enroll 1,800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.